{"entity":{"type":"insider","cik":"0001446830","url":"/insider/0001446830","json_url":"/insider/0001446830.json","name":"MILLENNIUM GROUP MANAGEMENT LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":101,"n_filings":22,"first":"2008-10-06","last":"2026-05-15","span_basis":"filed_date"},"name_variants":[{"name":"MILLENNIUM GROUP MANAGEMENT LLC","source":"filing","n_filings":5,"first_seen":"2020-06-04","last_seen":"2026-05-15"},{"name":"MILLENNIUM INTERNATIONAL MANAGEMENT GP LLC","source":"filing","n_filings":17,"first_seen":"2008-10-06","last_seen":"2014-01-10"}],"transactions":[{"id":6085367,"accession":"0001104659-26-062608","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001104659-26-062608","line_url":"/filing/0001104659-26-062608","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC; ENGLANDER ISRAEL A","owner_display_name":"MILLENNIUM GROUP MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8151.0,"shares_display":"8,151","price_per_share":31.011532008342535,"price_display":"31.01","price_state":"stated","total_value":252774.9974,"total_display":"252,775.00","total_whole":"252,775","shares_owned_after":133986.0,"shares_owned_after_display":"133,986","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-07","filed_date":"2026-05-15","scope":"insider","n_lines":5},{"id":6085354,"accession":"0001104659-26-062608","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001104659-26-062608","line_url":"/filing/0001104659-26-062608#line-12","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC; ENGLANDER ISRAEL A","owner_display_name":"MILLENNIUM GROUP MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1108.0,"shares_display":"1,108","price_per_share":33.38,"price_display":"33.38","price_state":"stated","total_value":36985.04,"total_display":"36,985.04","total_whole":"36,985","shares_owned_after":133986.0,"shares_owned_after_display":"133,986","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-07","filed_date":"2026-05-15","scope":"insider"},{"id":6085350,"accession":"0001104659-26-062608","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001104659-26-062608","line_url":"/filing/0001104659-26-062608","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC; ENGLANDER ISRAEL A","owner_display_name":"MILLENNIUM GROUP MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1259.0,"shares_display":"1,259","price_per_share":31.056301667990468,"price_display":"31.06","price_state":"stated","total_value":39099.8838,"total_display":"39,099.88","total_whole":"39,100","shares_owned_after":141029.0,"shares_owned_after_display":"141,029","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-06","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":6085341,"accession":"0001104659-26-062608","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001104659-26-062608","line_url":"/filing/0001104659-26-062608#line-9","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC; ENGLANDER ISRAEL A","owner_display_name":"MILLENNIUM GROUP MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1104.0,"shares_display":"1,104","price_per_share":31.02,"price_display":"31.02","price_state":"stated","total_value":34246.08,"total_display":"34,246.08","total_whole":"34,246","shares_owned_after":141029.0,"shares_owned_after_display":"141,029","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-06","filed_date":"2026-05-15","scope":"insider"},{"id":6085339,"accession":"0001104659-26-062608","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001104659-26-062608","line_url":"/filing/0001104659-26-062608","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC; ENGLANDER ISRAEL A","owner_display_name":"MILLENNIUM GROUP MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7666.0,"shares_display":"7,666","price_per_share":32.12098335507435,"price_display":"32.12","price_state":"stated","total_value":246239.4584,"total_display":"246,239.46","total_whole":"246,239","shares_owned_after":144974.0,"shares_owned_after_display":"144,974","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-02","filed_date":"2026-05-15","scope":"insider","n_lines":5},{"id":6085316,"accession":"0001104659-26-062608","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-062608","line_url":"/filing/0001104659-26-062608","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC; ENGLANDER ISRAEL A","owner_display_name":"MILLENNIUM GROUP MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2003.0,"shares_display":"2,003","price_per_share":35.013919121318025,"price_display":"35.01","price_state":"stated","total_value":70132.88,"total_display":"70,132.88","total_whole":"70,133","shares_owned_after":144974.0,"shares_owned_after_display":"144,974","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-02","filed_date":"2026-05-15","scope":"insider","n_lines":3},{"id":6226623,"accession":"0001104659-26-062605","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001104659-26-062605","line_url":"/filing/0001104659-26-062605","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ENGLANDER ISRAEL A","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1150.0,"shares_display":"1,150","price_per_share":31.649056,"price_display":"31.65","price_state":"stated","total_value":36396.4144,"total_display":"36,396.41","total_whole":"36,396","shares_owned_after":147731.0,"shares_owned_after_display":"147,731","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":6226615,"accession":"0001104659-26-062605","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001104659-26-062605","line_url":"/filing/0001104659-26-062605","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ENGLANDER ISRAEL A","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6175.0,"shares_display":"6,175","price_per_share":34.4905088582996,"price_display":"34.49","price_state":"stated","total_value":212978.8922,"total_display":"212,978.89","total_whole":"212,979","shares_owned_after":147731.0,"shares_owned_after_display":"147,731","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-05-15","scope":"insider","n_lines":3},{"id":6226603,"accession":"0001104659-26-062605","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001104659-26-062605","line_url":"/filing/0001104659-26-062605","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ENGLANDER ISRAEL A","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1591.0,"shares_display":"1,591","price_per_share":25.488857196731615,"price_display":"25.49","price_state":"stated","total_value":40552.7718,"total_display":"40,552.77","total_whole":"40,553","shares_owned_after":146657.0,"shares_owned_after_display":"146,657","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-05-15","scope":"insider","n_lines":5},{"id":6226585,"accession":"0001104659-26-062605","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001104659-26-062605","line_url":"/filing/0001104659-26-062605","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; ICS OPPORTUNITIES II LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ENGLANDER ISRAEL A","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6005.0,"shares_display":"6,005","price_per_share":28.1633493755204,"price_display":"28.16","price_state":"stated","total_value":169120.913,"total_display":"169,120.91","total_whole":"169,121","shares_owned_after":146657.0,"shares_owned_after_display":"146,657","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-05-15","scope":"insider","n_lines":7},{"id":5795970,"accession":"0001104659-26-062603","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":888.0,"shares_display":"888","price_per_share":26.612558333333332,"price_display":"26.61","price_state":"stated","total_value":23631.9518,"total_display":"23,631.95","total_whole":"23,632","shares_owned_after":145678.0,"shares_owned_after_display":"145,678","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-30","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":5795967,"accession":"0001104659-26-062603","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9533.0,"shares_display":"9,533","price_per_share":25.857067324032307,"price_display":"25.86","price_state":"stated","total_value":246495.4228,"total_display":"246,495.42","total_whole":"246,495","shares_owned_after":145678.0,"shares_owned_after_display":"145,678","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-30","filed_date":"2026-05-15","scope":"insider","n_lines":4},{"id":5795958,"accession":"0001104659-26-062603","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":505.0,"shares_display":"505","price_per_share":26.80824316831683,"price_display":"26.81","price_state":"stated","total_value":13538.1628,"total_display":"13,538.16","total_whole":"13,538","shares_owned_after":142360.0,"shares_owned_after_display":"142,360","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-27","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":5795954,"accession":"0001104659-26-062603","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15321.0,"shares_display":"15,321","price_per_share":26.611628464199466,"price_display":"26.61","price_state":"stated","total_value":407716.7597,"total_display":"407,716.76","total_whole":"407,717","shares_owned_after":142360.0,"shares_owned_after_display":"142,360","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-27","filed_date":"2026-05-15","scope":"insider","n_lines":3},{"id":5795948,"accession":"0001104659-26-062603","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1857.0,"shares_display":"1,857","price_per_share":28.12042644049542,"price_display":"28.12","price_state":"stated","total_value":52219.6319,"total_display":"52,219.63","total_whole":"52,220","shares_owned_after":131370.0,"shares_owned_after_display":"131,370","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-26","filed_date":"2026-05-15","scope":"insider","n_lines":2},{"id":5795944,"accession":"0001104659-26-062603","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603#line-4","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2601.0,"shares_display":"2,601","price_per_share":28.8539,"price_display":"28.85","price_state":"stated","total_value":75048.9939,"total_display":"75,048.99","total_whole":"75,049","shares_owned_after":131370.0,"shares_owned_after_display":"131,370","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-26","filed_date":"2026-05-15","scope":"insider"},{"id":5795942,"accession":"0001104659-26-062603","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603#line-3","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1327.0,"shares_display":"1,327","price_per_share":27.9467,"price_display":"27.95","price_state":"stated","total_value":37085.2709,"total_display":"37,085.27","total_whole":"37,085","shares_owned_after":131370.0,"shares_owned_after_display":"131,370","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-26","filed_date":"2026-05-15","scope":"insider"},{"id":5795940,"accession":"0001104659-26-062603","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-062603","line_url":"/filing/0001104659-26-062603#line-2","is_derivative":false,"issuer_cik":"0001017456","issuer_name":"Sensei Biotherapeutics, Inc.","issuer_ticker":"SNSE","issuer_name_source":null,"issuer_url":"/issuer/0001017456","owner_cik":null,"owner_name":"ICS OPPORTUNITIES II LLC; ENGLANDER ISRAEL A; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC","owner_display_name":"ICS OPPORTUNITIES II LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1025.0,"shares_display":"1,025","price_per_share":29.9788,"price_display":"29.98","price_state":"stated","total_value":30728.27,"total_display":"30,728.27","total_whole":"30,728","shares_owned_after":131370.0,"shares_owned_after_display":"131,370","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-26","filed_date":"2026-05-15","scope":"insider"}],"collapsed":true,"next_cursor":"2026-03-26|5795940","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001829802","name":"Sensei Biotherapeutics, Inc.","url":"/issuer/0001829802","role":"Ten percent owner","n_filings":3,"first_seen":"2026-05-15","last_seen":"2026-05-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001823466","name":"Duddell Street Acquisition Corp.","url":"/issuer/0001823466","role":"Ten percent owner","n_filings":1,"first_seen":"2021-12-21","last_seen":"2021-12-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001725872","name":"Megalith Financial Acquisition Corp","url":"/issuer/0001725872","role":"Other","n_filings":1,"first_seen":"2020-06-04","last_seen":"2020-06-04"},{"type":"issuer","type_label":"ISSUER","cik":"0000017485","name":"LIBERATOR MEDICAL HOLDINGS, INC.","url":"/issuer/0000017485","role":"Other","n_filings":8,"first_seen":"2010-05-28","last_seen":"2014-01-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001430725","name":"Global Ship Lease, Inc.","url":"/issuer/0001430725","role":"Other","n_filings":8,"first_seen":"2008-10-06","last_seen":"2009-02-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001390332","name":"STONE TAN CHINA ACQUISITION CORP.","url":"/issuer/0001390332","role":"Other","n_filings":1,"first_seen":"2008-12-24","last_seen":"2008-12-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001446830","retrieved_at":"2026-08-22T23:12:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}